Estrella Immunopharma (ESLA) Earnings Analysis

Estrella Immunopharma (ESLA) next reports earnings on 2026-09-02, consensus EPS -0.09 USD. Last quarter (2026-05-15) it beat with EPS -0.05 USD vs -0.084 USD est (+40.5%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -2.20.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ESLA next report earnings?

Next earnings date2026-09-02
Consensus EPS estimate-0.09 USD
Revenue estimaten/a

ESLA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.05 USD-0.084 USD+40.5%Beat
2026-03-18-0.0162 USD-0.18 USD+91%Beat
2025-11-12-0.13 USD-0.1865 USD+30.3%Beat
2025-08-11-0.15 USD-0.07 USD-114.3%Miss
2025-05-14-0.06 USD-0.11 USD+45.5%Beat
2025-02-15-0.12 USD-0.12 USD0%Beat
2024-11-14-0.09 USDn/an/an/a

Beat rate: 5/6 (83%) over reported quarters with consensus data.

ESLA valuation and analyst view

Trailing P/E-2.20
Trailing EPS-0.3146 USD
Price / book-6.08
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (1 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Estrella Immunopharma (ESLA)'s next earnings date?

Estrella Immunopharma is next scheduled to report on 2026-09-02, with a consensus EPS estimate of -0.09 USD.

Did ESLA beat earnings last quarter?

In its 2026-05-15 report, ESLA posted EPS of -0.05 USD versus a -0.084 USD estimate — a beat of 40.5%.

What is ESLA's earnings track record?

Over the last 6 reported quarters with consensus data, ESLA beat estimates 5 times (83%).

What is ESLA's current P/E ratio and EPS?

ESLA trades at a trailing P/E of -2.20 on trailing EPS of -0.3145994018433765 USD.

What do analysts rate ESLA?

Analyst consensus is "Buy" across 1 ratings (0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell).